Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis

Area of Science:

• Biomedical Science
• Immunology
• Muscle Biology

Background:

• Duchenne muscular dystrophy (DMD) involves skeletal muscle fiber necrosis due to dystrophin deficiency.
• Inflammatory cells and cytokines, like tumor necrosis factor-alpha (TNFalpha), may worsen muscle damage in DMD.
• Dystrophic mdx mice serve as a model to study DMD pathology and test therapeutic interventions.

Purpose of the Study:

• To investigate if blocking TNFalpha activity can prevent or reduce muscle necrosis in mdx mice.
• To determine the role of TNFalpha in exacerbating muscle membrane breakdown in dystrophin-deficient muscle.
• To evaluate the therapeutic potential of anti-TNFalpha antibodies for DMD.

Main Methods:

• Young mdx mice were treated weekly with the anti-TNFalpha antibody Remicade from 7 days of age.
• Histological analysis was performed from 18 to 28 days postnatally to assess inflammation, muscle necrosis, and myotube formation.
• Muscle damage was visualized using Evans blue dye penetration, and results were compared to control mdx mice and mdx/TNFalpha-/- mice.

Main Results:

• Remicade treatment significantly delayed and reduced skeletal muscle fiber breakdown in mdx mice.
• Pharmacological blockade of TNFalpha activity provided marked protection against muscle damage.
• No adverse effects on new muscle formation were observed in Remicade-treated mice.
• Comparison with mdx/TNFalpha-/- mice further supported TNFalpha's role in muscle necrosis.

Conclusions:

• TNFalpha contributes significantly to skeletal muscle necrosis in the mdx mouse model of DMD.
• Blocking TNFalpha activity with Remicade demonstrates a protective effect against muscle breakdown.
• Anti-inflammatory strategies targeting TNFalpha represent a promising therapeutic avenue for Duchenne muscular dystrophy.